health / medicine2 months ago

ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM

finance.yahoo.com
Open in Finance.yahoo.com
Vote 1
0

References

Ozempic isn't just for weight loss. A new study says it may reverse signs of fatty liver disease, too.

Ozempic isn't just for weight loss. A new study says it may reverse signs of fatty liver disease, too.

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 351 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement